C. Glenn Begley
From 2002 to 2012, Dr Begley was Vice-President and Global Head of Hematology and Oncology Research, Amgen Inc., California. He joined Amgen in 2002, and was responsible for building the Hematology and Oncology research program, and for the strategy, coordination and integration of the research effort at Amgen sites in Thousand Oaks CA, San Francisco CA, Seattle WA, Burnaby BC, and Cambridge MA.
His scientific responsibilities included Amgen marketed products (Neupogen, Neulasta, Kepivance, Stemgen, Aranesp, Nplate, Xgeva) which involved preparation and presentations for multiple FDA face-to-face meetings, multiple FDA Drug Advisory Committee meetings, and interactions with medical and scientific opinion leaders and patient advocate groups. In addition, over 25 clinical-stage molecules emerged from his Department, including fully human antibodies, small molecules, protein ligands and antibody-drug conjugates. A key element of involved the development of biomarkers and clinical strategy for early phase trials.
He was responsible for in-licensing of the bi-specific T-cell engager (BiTE) molecule blinatumomab, and the oncolytic virus talimogene laherparepvec (T-Vec), both of which were the first molecules of the class that were approved by the FDA for cancer treatment.
Before joining Amgen, he had over 20 years of clinical experience in medical oncology and hematology. His personal research focused on regulation of hematopoietic cells and translational clinical trials.
He has received numerous honors and awards, including being elected as the first Foreign Fellow to the American Society of Clinical Investigation in 2000, and to the prestigious Association of American Physicians in 2008. In 2014 he was an inaugural inductee into the "Hall of Fame" at his alma mater, the Royal Melbourne Hospital, and elected to the Australian Academy of Health and Medical Sciences.
He has published 404 papers that have >29,552 citations and 11 granted Patents. His H-index is 80 and his online videos related to translational research have >23,000 views.
While at Amgen, he highlighted the issue of research integrity and scientific reproducibility and its importance for translational research. Since then he has made multiple presentations on the subject of scientific integrity including to President Obama's Science Council, the White House, US National Institutes of Health, US Academies of Science, US National Institute of Standards and Technology, the British Broadcasting Company, the Wellcome Trust, Australian National Health and Medical Research Council, and numerous Universities, Research Institutes and companies.